Xenograft, Pancreas, Orthotopic, Bx-PC3-Luc

ITEM 581522

CONTACT FOR PRICING

STATUS Available

CONTACT CUSTOMER SERVICE

^{ADD TO FAVORITES}

^{ADD TO PANEL}

OVERVIEW

DOCUMENTS/REFERENCES

RELATED SERVICES

RELATED PRODUCTS

BIOLOGICAL INFORMATION

BACKGROUND INFORMATION

The human pancreatic carcinoma Bx-PC3-Luc orthotopic model is used to evaluate therapeutic efficacy of investigational antineoplastic and/or antimetastatic agent(s) in immune-compromised mice.

ORGANISM

Mouse

ASSAY INFORMATION

ASSAY TYPE

In Vivo

TESTING INFORMATION

PROCEDURE SUMMARY

Specific-pathogen-free (SPF) female NOD/SCID mice bred in an animal isolator (IVC racks) under SPF conditions at 22 ± 2°C are used. Viable luciferase labeled human pancreatic adenocarcinoma BxPC-3-Luc cells, at 1 x 10⁶ cells per mouse, are injected orthotopically into the pancreas of each experimental animal. Dose administrations are initiated approximately 7 days post tumor implantation (total flux approximately 5E9 photons per second (Day 1). Tumor volumes (by bioluminence signal) and body weights are measured and recorded twice weekly over the course of the study period. Study period can be up to 2 weeks or when the mean tumor volume reaches 2000 mm³. The treatment initiation day and study period can be tailored to meet therapeutic needs. Regions of interest encompassing the intracranial area of a signal will be defined using IVIS Spectrum, and the total number of photons per minute [counts/min (cpm)] will be recorded.

CRITERIA FOR SIGNIFICANCE

A %T/C value ≤ 42% or significant difference (p < 0.05) in tumor volume.

TURNAROUND TIME

STANDARD

60 Days

CLINICAL RELEVANCE

THERAPEUTIC AREA

Oncology/Immuno-Oncology

ADDITIONAL INFORMATION

BRAND

PDS

TESTING LOCATION

Taiwan - Taipei

OTHER INFORMATION

We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.